Abstract
Radiopharmaceuticals contain a radionuclide and an agent to direct the radionuclide to a receptor, antigen, ionic pump, or other sites of interest. Some radiopharmaceuticals are simple, such as the ionic form of the radionuclide, while most radiopharmaceuticals have a complex chemical structure where the radionuclide provides a signal, indicating the site of localization of the carrier molecule.
Common single-photon radiopharmaceuticals used for oncological diagnosis include the agents labeled with 99mTc such as 99mTc-bisphosphonates (that accumulate at sites of bone mineral deposition), 99mTc-labeled colloids (that are used for lymphoscintigraphy and for imaging of the liver and spleen), 99mTc-hexakis-methoxy-isobutyl-isonitrile, and 99mTc-tetrofosmin (initially employed for myocardial perfusion imaging, and also used for localization of parathyroid adenomas and for identification of other malignant tumors).
The most commonly used radiopharmaceuticals labeled with radioiodine (123I or 131I) include iodide itself (for localization of thyroid tissue) and the catecholamine analog metaiodobenzylguanidine (MIBG, for localizing pheochromocytoma and neuroblastoma). Thallium-201 chloride (201Tl) is used for myocardial perfusion imaging as well as tumor perfusion imaging, while 111In-pentetreotide detects overexpression of somatostatin receptors, especially in neuroendocrine tumors and in lesions arising from the neural crest, such as carcinoid, paragangliomas, and medullary thyroid carcinomas. 111In-capromab pendetide is a murine monoclonal antibody recognizing a transmembrane glycoprotein expressed by poorly differentiated and metastatic prostate adenocarcinomas. 67Ga-citrate receptors are overexpressed on membranes of both tumor and inflammatory cells.
Similar content being viewed by others
Abbreviations
- COMT:
-
Catecholamine-O-methyltransferase
- COPD:
-
Chronic obstructive pulmonary disease
- DIT:
-
Diiodotyrosine
- DTPA:
-
Diethylenetriaminepentaacetic acid
- EDDA:
-
Ethylenediamine-N,N′-bis(2-hydroxyphenyl)acetic acid
- EMA:
-
European Medicines Agency
- [18F]FDG:
-
2-Deoxy-2-[18F]fluoro-d-glucose
- FDA:
-
United States Food and Drug Administration
- HYNIC:
-
6-Hydrazinopyridine-3-carboxylic acid, also known as hydrazidonicotinic acid/hydrazinonicotinamide
- LDL:
-
Low-density lipoproteins
- [123I]MIBG:
-
meta-[123I]Iodobenzylguanidine
- [131I]MIBG:
-
meta-[131I]Iodobenzylguanidine
- MAO:
-
Monoamine oxidase
- MIBG:
-
Meta-iodobenzylguanidine
- MIT:
-
Monoiodotyrosine
- NIS:
-
Sodium–iodide symporter
- PET:
-
Positron emission tomography
- PSMA:
-
Prostate-specific membrane antigen
- ROLL:
-
Radioguided occult lesion localization
- SLN:
-
Sentinel lymph node
- SPECT:
-
Single-photon emission tomography
- SST:
-
Somatostatin
- SSTR:
-
Somatostatin receptor
- 99mTc-DTPA:
-
99mTc-Diethylenetriaminepentaacetic acid
- 99mTc-HDP:
-
99mTc-Hydroxyethylenediphosphonate
- 99mTc-MAA:
-
99mTc-Macroaggregated albumin
- 99mTc-MDP:
-
99mTc-Methylene diphosphonate
- TSH:
-
Thyroid-stimulating hormone
Suggested Readings
Ell PJ, Gambhir SS, editors. Nuclear medicine in clinical diagnosis and treatment. 3rd ed. New York: Churchill Livingston; 2004.
Herbert JC, Eckelman WC, Neumann RD, editors. Nuclear medicine – diagnosis and therapy. New York: Thieme Medical Publishers; 1996.
IAEA. Operational guidance on hospital radiopharmacy. Vienna: International Atomic Energy Agency (IAEA); 2008.
IAEA. Technetium-99m radiopharmaceuticals: status and trends. Vienna: International Atomic Energy Agency (IAEA); 2010.
IAEA. Radiopharmaceuticals for sentinel lymph node detection: status and trends. Vienna: International Atomic Energy Agency (IAEA); 2015.
IAEA. Good practice for introducing radiopharmaceuticals for clinical use. Vienna: International Atomic Energy Agency (IAEA); 2015.
Kowalsky RJ, Weatherman KD. Radiopharmaceuticals in nuclear pharmacy and nuclear medicine. 4th ed. American Pharmacists Association; 2020.
Lewis JS, Windhorst AD, Zeglis BMM, editors. Radiopharmaceutical chemistry. Cham: Springer; 2019.
Owunwanne A, Patel M, Sadek S, editors. The handbook of radiopharmaceuticals. New York: Springer; 1995.
Schwochau K, editor. Technetium: chemistry and radiopharmaceuticals. Hoboken: Wiley; 2000.
Theobald T, editor. Sampson’s textbook of radiopharmacy. 4th ed. London: Pharmaceutical Press; 2010.
Vallabhajosula S. Molecular imaging – radiopharmaceuticals for PET and SPECT. New York: Springer; 2009.
Volterrani D, Erba PA, Carriò I, Strauss HW. Mariani G, editors. Nuclear Medicine Textbook - Methodology and Clinical Applications. Cham, Switzerland: Springer Nature Switzerland AG; 2019.
Welch MJ, Redvanly CS, editors. Handbook of radiopharmaceuticals: radiochemistry and applications. Hoboken: Wiley; 2003.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
Orsini, F., Puta, E., Lorenzoni, A., Erba, P.A., Mariani, G. (2022). Single-Photon Emitting Radiopharmaceuticals for Diagnostic Applications. In: Volterrani, D., Erba, P.A., Strauss, H.W., Mariani, G., Larson, S.M. (eds) Nuclear Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-26067-9_2-3
Download citation
DOI: https://doi.org/10.1007/978-3-319-26067-9_2-3
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-26067-9
Online ISBN: 978-3-319-26067-9
eBook Packages: Springer Reference MedicineReference Module Medicine
Publish with us
Chapter history
-
Latest
Single-Photon Emitting Radiopharmaceuticals for Diagnostic Applications- Published:
- 20 May 2022
DOI: https://doi.org/10.1007/978-3-319-26067-9_2-3
-
Single-Photon Emitting Radiopharmaceuticals for Diagnostic Applications
- Published:
- 02 April 2022
DOI: https://doi.org/10.1007/978-3-319-26067-9_2-2
-
Original
Single-Photon Emitting Radiopharmaceuticals for Diagnostic Applications- Published:
- 21 October 2016
DOI: https://doi.org/10.1007/978-3-319-26067-9_2-1